- About Us
- Clinical Trials
- News & Publications
- Business Development
May 20, 2013
At this years annual meeting of the American Society of Clinical Oncology (ASCO) held from May 31 to June 4, in Chicago, Illinois; SOTIO will for the first time ever introduce itself to the worldwide oncology community.
Conference participants will have opportunities to meet SOTIO on various occasions:
1. At SOTIO’s booth No. 12136 in Zone B2; members of SOTIO’s Science and Medical team will be available to welcome and introduce interested investigators and researchers to SOTIO’s research plans and the manufacturing of its proprietary Active Cellular Immunotherapy (ACI).
2. SOTIO is organizing an Informational Meeting with potential investigators interested in the Phase III VIABLE clinical trial (SOTIO plans to launch this phase in the latter half of this year). The meeting will take place at the Hilton Hotel (720 S Michigan Ave., Chicago, IL) in the Northwest 4, Lower Level meeting room on June 1 at 6:30 pm. The meeting will be attended by the Coordinating Investigator of the Phase III VIABLE clinical trial, Associate Professor Susan F. Slovin, MD, PhD; an associate member in the Genitourinary Oncology Service at the Memorial Sloan-Kettering Cancer Center in New York, U.S.; and also a member of SOTIO’s Science and Medical Leadership team. (Invitation only, contact Machado@sotio.com to confirm attendance)
3. Presentation of one poster during General Poster Session (Board #18C), on June 3 from 8:00 am to 11:45 am: "High hydrostatic pressure to induce immunogenic cell death in human tumor cells" (for more information please see http://meetinglibrary.asco.org/content/116816-132)
4. Public release of two abstracts containing the results of the research in connection with the ASCO annual meeting 2013: "Phase I/II clinical trials of dendritic cell-based immunotherapy in patients with biochemical relapse of prostate cancer" (for more information please see http://meetinglibrary.asco.org/content/116902-132) and "Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T cells" (for more information please see http://meetinglibrary.asco.org/content/116817-132)
For more information about the ASCO Annual Meeting 2013 please visit http://chicago2013.asco.org/